Ivim Health GLP-1 Weight Loss: Cost Breakdown, Clinical Data, and What They Don't Tell You (2026)
An Independent Pricing Audit, Compounded Semaglutide Safety Facts, Cancellation Terms, and a Published 1,131-Patient Study - Examined Before You Enroll
COLUMBUS, OHIO / ACCESS Newswire / February 23, 2026 / Disclaimer: This article is for informational purposes only and does not constitute medical advice. Weight management concerns should be evaluated by qualified healthcare professionals. Always consult a qualified healthcare professional before starting any prescription treatment. This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you.
Ivim Health GLP-1 ID Program (2026): Pricing, Clinical Data, and What to Know Before You Sign Up
You saw the ad. Maybe it was on Instagram between stories, or a sponsored post on Facebook, or a TikTok that stopped your scroll. A before-and-after transformation. Weight loss claims. Something about "individualized dosing." And now you're here, doing exactly what a smart consumer should do - researching before you spend a dollar.
If you're searching terms like "Ivim Health review" or "Ivim Health cost," you're likely trying to verify pricing, safety, the compounded medication distinction, and whether this program fits your specific situation. GLP-1 ads are everywhere, and the telehealth market is more crowded and confusing than ever. That's exactly what this guide covers.
Here's what you'll find: the compounded medication distinction most sites gloss over, the real total cost structure including program fees, the company's published clinical study with its limitations fully acknowledged, and a self-assessment framework to determine whether this model fits your needs.
Compounded medications are not FDA-approved products. Ivim Health's GLP-1 ID program primarily uses compounded semaglutide and compounded tirzepatide prepared by licensed pharmacies based on individual prescriptions. Compounded medications are not reviewed or approved by the FDA as finished products and have not undergone FDA review for safety, effectiveness, or quality. This distinction matters enormously, and we dedicate an entire section to explaining exactly why.
You can review the program details and confirm current pricing on the official Ivim Health GLP-1 ID page before deciding.
Ivim Health GLP-1 ID at a Glance (2026)
Program Type: Telehealth GLP-1 weight management (virtual consultations + medication delivery)
Medication: Primarily compounded semaglutide and compounded tirzepatide (not FDA-approved finished products)
Published Study: 1,131 completers, 19.5% average body weight reduction at 52 weeks (retrospective, company-authored, no control group)
Starting Cost: Approximately $75-$133/month medication + $74.99/month program fee (verify current pricing on official website)
Cancellation Policy: No cancellation once program term begins (1, 2, 4, or 6 months)
Prescription Required: Yes - clinical eligibility determined solely by a licensed clinician after medical evaluation
Coverage: 49 U.S. states (Mississippi excluded); HSA/FSA may apply per your plan
Common Search Questions Addressed in This Guide
Ivim Health review 2026 - Is Ivim Health legit? - Ivim Health GLP-1 cost per month - Compounded semaglutide vs Wegovy - Ivim Health cancellation policy - Ivim Health side effects - Ivim Health clinical study - Is compounded semaglutide safe?
How This Review Was Researched
This guide was developed by reviewing the following primary sources and will reference them throughout:
The official Ivím Health website (ivimhealth.com), including the GLP-1 ID landing page, membership page, compounded semaglutide product page, pricing pages, FAQ sections, safety information pages, providers page, returns policy, and terms and conditions. The peer-reviewed published study: Duncan et al., "Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes," Obesity Pillars, 2025 (PubMed indexed). FDA guidance on compounded semaglutide and the 503A compounding framework. General industry pricing data on brand-name GLP-1 medications. Published Ivím Health press releases from 2025 regarding clinical outcomes, advocacy positions, and the GLP-1 ID program launch.
No claims in this article are based on unverifiable sources, undisclosed insider information, or assumptions. Every factual claim is attributed to a specific, publicly accessible source. Where information could not be independently verified, it is clearly labeled as company-reported. All medical, regulatory, and pricing claims were cross-referenced against publicly accessible primary sources at the time of publication (February 2026).
What Is Ivim Health and Who Is Behind It?
Before evaluating any telehealth weight loss program, you should know who you're dealing with. According to publicly available information, Ivim Health (Ivim Services LLC) is a telehealth weight loss platform that lists its contact address at 4200 Regent Street, Suite 200, Columbus, OH 43219. The company's terms of use reference a registered office in Brighton, Michigan. The company was founded in 2021 by Dr. Taylor Kantor, alongside his brother Anthony and Anthony's wife, Kelly, according to the company's website.
The company describes its mission as reimagining care for cardiometabolic conditions by making it more accessible, individualized, and data-driven. Their approach is built around what they call IVIM - Individualized Virtual Integrative Medicine - which blends medical precision with a holistic mindset, according to their about page.
The company states it operates across 49 U.S. states, with Mississippi excluded due to state telehealth laws regarding medical weight management, according to data from their published clinical study. Availability is subject to provider licensure and state regulations. According to the company's published materials, the platform maintains a nationwide network of licensed medical providers. According to the company's published materials, Ivím Health reports serving over 470,000 patients and having more than 25,000 five-star reviews on Trustpilot at the time of this article's publication. These figures are company-reported and have not been independently verified.
One element that distinguishes Ivim Health from many competitors in this space is that the company has published clinical outcomes data in a peer-reviewed journal - specifically Obesity Pillars, which is indexed on PubMed Central. We'll break down exactly what that study shows, and what its limitations are, later in this guide.
How the Ivim Health Platform Actually Works: The Three-Entity Model You Need to Understand
This may be the single most important section for anyone considering any telehealth weight loss platform - not just Ivim Health. The company itself is not your doctor. This distinction is foundational to understanding how your care is actually delivered.
Ivim Health (Ivim Services LLC) functions as the telehealth platform facilitating connections between patients and healthcare providers. According to the platform's terms of use, Ivim Health itself is not a healthcare provider. The platform provides the technology infrastructure, the Ivim Health App for progress tracking and weekly check-ins, customer service, care coordination, holistic consultations, master classes, group coaching, and community access. Think of it as the operating system that connects you to clinical care - not the care itself.
Licensed Medical Providers are the clinicians who review your health information, conduct consultations, and determine whether prescriptions are appropriate. According to the company's providers page, providers include board-certified obesity specialists, nurse practitioners, and health coaches described as employed by Ivím Health. However, the company's terms of use contain language referencing third-party providers and independent clinical decision-making. The company states these providers make clinical decisions based on individual patient evaluations. The platform cannot guarantee that any individual will receive a prescription, as that determination rests entirely with the evaluating clinician. Clinical eligibility is determined solely by the evaluating licensed provider. This is an important distinction - you're not buying a prescription, you are accessing a clinical evaluation.
Partner Pharmacies fulfill prescriptions written by the medical providers. According to the company's published information, these are licensed U.S. pharmacies that compound and dispense medications. According to the company's compounded semaglutide page, "Ivím only selects FDA-inspected, state-regulated compounding pharmacies that meet regulatory board standards for quality and safety." Inspection of a pharmacy does not mean the compounded finished product itself is FDA-approved. The company also states its partnered pharmacies maintain internal quality-control measures and testing programs. The finished compounded product itself, however, has not been independently reviewed by the FDA as a finished product.
This three-entity structure - platform, clinical team, pharmacies - provides separation between technology coordination, clinical decision-making, and medication dispensing. The company's providers page describes its clinicians as employed by the company, though the terms of use contain separate language about third-party providers. Clarify the employment model during your consultation. Understanding this structure helps you set realistic expectations: the quality of your experience will depend significantly on the individual clinician assigned to your case, not just the platform's branding.
What Is GLP-1 ID (Individualized Dosing) and Why Does It Matter?
The core differentiator Ivim Health promotes is its GLP-1 ID model, which stands for Individualized Dosing. According to the company, this approach means your care is fully individualized - reflecting your body's rhythm, your lifestyle, and your goals, one week at a time. That's a direct quote from their website, and it represents a specific claim about how the program differs from competitors. The impact of weekly monitoring on outcomes has not been isolated in randomized controlled trials.
Here's what the company says this looks like in practice:
You complete weekly check-ins through the Ivim Health App, reporting your symptoms, progress, and how you are feeling on the current dose. According to the GLP-1 ID program page, your assigned provider reviews these check-ins and makes clinician-guided dosing decisions based on your feedback. The company positions this as distinct from a standard fixed escalation schedule.
The company's comparison chart positions this model as distinct from both traditional in-clinic medicine (which they characterize as offering limited individualization) and other telehealth competitors (which they characterize as using basic personalized care based on general patterns rather than truly individualized protocols).
Why does this matter to you as a potential patient? The standard semaglutide dosing approach - as described on Ivím's own safety information pages for branded medications - involves dose increases on approximately a four-week cadence. The GLP-1 ID program's "weekly dose adjustments" claim refers to weekly check-ins where your provider CAN adjust your dose based on your response, not that your dose necessarily changes every week. The practical distinction is that the check-in frequency creates more opportunities for adjustment, rather than waiting until a predetermined escalation point. Whether this frequency produces different outcomes for you depends on your individual medication response, side effect tolerance, and how actively your assigned provider engages with your check-in data.
This is the company's positioning, and it's a reasonable clinical concept. That said, the individualized dosing approach hasn't been independently compared head-to-head against standard dosing protocols in a randomized controlled trial. The company's published study demonstrates outcomes within their protocol, but doesn't isolate the individualized dosing variable from other program elements like holistic consultations, coaching, and community support.
Understanding Compounded GLP-1 Medications: The Section Most Reviews Skip
This is the section that separates an informed decision from a blind one. If you only read one part of this guide, make it this one.
Ivim Health's GLP-1 ID program primarily uses compounded semaglutide and compounded tirzepatide. These contain the same active ingredients as the brand-name FDA-approved medications Wegovy (semaglutide, manufactured by Novo Nordisk) and Zepbound (tirzepatide, manufactured by Eli Lilly) - but they're not the same products. According to Ivim Health's own disclaimers, the company has no affiliation with Novo Nordisk, and the compounded semaglutide products available through their program are not made by Novo Nordisk or any company affiliated with Novo Nordisk.
Here's the critical distinction you need to understand:
FDA-approved medications like Wegovy and Zepbound have undergone rigorous FDA review for safety, effectiveness, and quality as finished products. They are manufactured under strict FDA manufacturing oversight by specific pharmaceutical companies with verified production processes.
Compounded medications are prepared by licensed compounding pharmacies based on individual prescriptions. According to Ivim Health's safety information, while federal law allows the prescription of compounded drugs, they are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review by the FDA. The FDA does not verify the safety, effectiveness, or quality of compounded semaglutide as a finished product. According to the company's compounded semaglutide page, "Ivím only selects FDA-inspected, state-regulated compounding pharmacies that meet regulatory board standards for quality and safety." Inspection of a pharmacy does not mean the compounded finished product itself is FDA-approved. The company also states its partnered pharmacies maintain internal quality-control measures and testing programs - but the finished compounded product itself has not been independently reviewed by the FDA before reaching you.
This is a meaningful regulatory distinction that affects oversight standards, product review processes, and what guarantees exist about the specific product you receive.
FDA safety communications regarding compounded semaglutide: The FDA has issued specific warnings about compounded GLP-1 products that every potential patient should be aware of. According to FDA safety communications, the agency has raised concerns about dosing errors with compounded injectable semaglutide - including reports of patients receiving incorrect doses that led to adverse events. The FDA has also raised concerns that some compounded products may use semaglutide salt forms rather than the base form used in FDA-approved products, which may affect dosing accuracy and bioavailability. Patients should ask their prescribing clinician whether the pharmacy uses semaglutide base form and how dosing equivalency is determined. These are not theoretical risks - they are documented safety concerns that underscore why the choice between compounded and FDA-approved medications should be made carefully with your prescribing clinician, who can discuss the specific pharmacy and quality assurance protocols involved in your prescription.
Why compounded GLP-1 medications exist: Compounded medications serve an important role in healthcare. They allow pharmacies to prepare customized formulations when a patient requires a dose outside commercially available options, when brand-name products face supply shortages, or when cost makes FDA-approved versions inaccessible. The semaglutide market has been significantly affected by supply shortages - the FDA determined in February 2025 that the shortage of semaglutide injection had ended, but compounded versions remain widely used due to their lower cost.
What Ivim Health offers beyond compounded options: According to the company's website, patients who prefer branded medications still have full access to FDA-approved Zepbound and Wegovy through Ivim Health's traditional GLP-1 program. The company also states it works to facilitate insurance access to brand-name treatments and offers exclusive Ivim discounts on brand-name medications. If you specifically want FDA-approved products, ask about these options during your consultation.
HSA and FSA eligibility: According to the company, compounded semaglutide medication can be paid for with your HSA or FSA card. Verify this with your specific plan administrator, as policies vary.
Why Compounded GLP-1 Regulatory Transparency Matters in 2026
If you've made it this far, you already understand more about compounded medications than most people who sign up for telehealth weight loss programs. That's not an accident - understanding the regulatory landscape around compounded GLP-1 medications in 2026 matters for making an informed decision, and most marketing materials don't explain it.
Here's the bigger picture you should be aware of:
The FDA 503A compounding framework is what governs most compounding pharmacies that fill prescriptions for individual patients. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed pharmacies can compound medications based on individual prescriptions from licensed practitioners. Outsourcing facilities may operate under Section 503B, which involves different oversight requirements. This is the legal framework under which most compounded semaglutide and tirzepatide is prepared. It is legal, it is well-established in U.S. healthcare, and it serves patients who need customized formulations or cannot access commercially available products - but it operates under different oversight standards than FDA-approved manufacturing.
The semaglutide shortage context matters for understanding why compounded GLP-1 became so widespread. During the branded semaglutide shortage - which the FDA determined ended in February 2025 - compounding pharmacies were permitted to prepare copies of the drug under shortage provisions. The end of that shortage has implications for the ongoing regulatory environment around compounded semaglutide, and patients should stay informed about how evolving FDA guidance may affect compounded product availability. FDA drug shortage status and enforcement posture have changed over time - verify the current status directly with FDA's drug shortage database and discuss availability with your prescriber and pharmacy. This regulatory environment is actively evolving, and informed patients ask about it.
What this means for you as a consumer: The distinction between FDA-approved and compounded is a factual regulatory difference that you should understand before making a healthcare decision. Transparent platforms explain this distinction clearly. The fact that you are reading about it here means you're doing your due diligence the right way.
Regardless of which telehealth platform you ultimately choose, ask these questions: Where is my medication being compounded? Is the pharmacy operating under 503A or 503B provisions? What quality assurance and testing processes does the pharmacy follow? Does the compounding pharmacy use semaglutide base form or a salt form, and how does that affect my dosing? What steps are in place to prevent dosing errors with injectable compounded medications? How does the end of the branded semaglutide shortage affect my compounded prescription availability going forward? Your prescribing clinician should be able to address these questions as part of your evaluation.
What the Published Clinical Study Actually Shows - And What It Does Not
One of the strongest elements of Ivim Health's credibility is that the company has published clinical data in a peer-reviewed journal. Many telehealth weight loss platforms make outcome claims without published evidence. Ivim Health's study appeared in Obesity Pillars, is indexed on PubMed Central, and provides transparent data on their protocol's outcomes. That matters. But the study also has important limitations that you should understand.
Study Citation: Duncan et al., "Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes," Obesity Pillars, 2025 (PubMed indexed). The full study is publicly accessible through PubMed Central for anyone who wants to read the primary source.
Official Website for Independent Verification: https://www.ivimhealth.com
What the study found (according to the published data):
The study examined 1,131 patients with BMI of 30 or greater who completed at least 365 days on semaglutide while following the IVIM protocol. At 52 weeks, patients lost an average of 19.5% of total body weight. Nearly half the patients (47.8%) achieved 20% or more weight reduction. At 68 weeks, patients who continued lost an average of 21.8% of body weight. This outcome reflects a retrospective analysis of program completers and should not be interpreted as typical or guaranteed for all patients.
The weight loss milestones are notable: according to the study, 99.2% of patients lost at least 5% of their body weight at 52 weeks, 93.9% lost 10% or more, 73.5% lost 15% or more, and 47.8% lost 20% or more. These figures reflect the specific study population - patients who completed at least 365 days on the protocol - and may not represent real-world discontinuation patterns or outcomes for all patients who begin the program.
The study also reported that over 95% of patients experienced side effects that were minimal or moderate but manageable, with only 3.3% reporting severe side effects during therapy.
Regarding medication breakdown, the study reported that 95.4% of patients were on compounded semaglutide while only 4.6% used branded semaglutide - a split the authors note was largely driven by supply shortages of branded semaglutide during the study period.
The company's cross-trial comparison - important context: The company's website references comparisons between the IVIM protocol outcomes and results from other published GLP-1 clinical trials. However, per the company's own disclosure, these were not head-to-head studies and should not be interpreted as direct superiority. The referenced comparison trial included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks - a fundamentally different protocol with different study populations, different variables, and different timeframes. Cross-trial comparisons are inherently limited and do not establish that one approach produces better results than another.
What the study does NOT prove:
No independent head-to-head trials comparing Ivím Health's protocol to other telehealth GLP-1 programs were identified at the time of publication.
This was a retrospective analysis, not a randomized controlled trial. Key limitations to understand:
Retrospective design - Data was analyzed after the fact, not collected prospectively under controlled conditions.
No control group - There was no comparison group receiving standard GLP-1 dosing without the IVIM protocol, so you can't isolate which specific elements of the program drove the results.
Self-selected completers - Patients were self-selected, meaning people who stuck with the program for a full year may be inherently more motivated than average. Only program completers were included.
Company-affiliated authors - The study was authored by Ivim Health employees, which does not invalidate the research but is a conflict of interest you should be aware of.
These are standard limitations that apply to most telehealth outcome studies. The fact that Ivim Health published data at all - and in a peer-reviewed journal - is a point in their favor compared to competitors who make outcome claims without any published evidence.
Clinical Evidence Summary
Study Type: Retrospective analysis (not a randomized controlled trial)
Participants: 1,131 program completers with BMI ≥30
Duration: 52-68 weeks
Primary Outcome: 19.5% average body weight reduction at 52 weeks
Medication: 95.4% compounded semaglutide, 4.6% branded semaglutide
Control Group: None
Funding/Authors: Ivím Health-affiliated authors (conflict of interest disclosed)
Publication:Obesity Pillars, 2025 (PubMed indexed, peer-reviewed)
Key Limitation: Self-selected completers; results should not be assumed typical for all patients
The Real Cost: Pricing, Program Fees, and What the Ads May Not Emphasize
Pricing transparency is where many telehealth platforms lose trust. Let's break down the actual cost of Ivim Health's GLP-1 ID program based on the company's published information - with an important caveat: Ivím Health presents pricing in different formats across different pages of their website, so we'll show you what we found and strongly recommend you verify current pricing directly before committing.
Medication Costs (according to the company's FAQ):
Compounded Semaglutide: Starting at approximately $75 per month
Compounded Tirzepatide: Starting at approximately $133 per month
Membership/Program Fee (according to the company): $74.99 per month, required for the duration of your medication plan. This fee covers provider access, weekly check-ins through the app, 1:1 virtual holistic consultations (which the company values at $850), master classes, group coaching, community access (valued at $500 by the company), a 20% discount on physician-formulated supplements, and access to the Ivim Health App.
Total Estimated Monthly Cost:
If you choose compounded semaglutide: approximately $150 per month ($75 medication + $74.99 program fee)
If you choose compounded tirzepatide: approximately $208 per month ($133 medication + $74.99 program fee)
These are starting prices per the company's published FAQ. Actual costs may vary based on your dosing requirements, program duration, and any active promotions. The company's GLP-1 ID marketing page may show different bundled figures - always confirm the specific pricing breakdown at checkout before committing. Verify current pricing directly on the official Ivim Health website before making any financial commitment.
Enrollment does not guarantee a prescription. Eligibility is determined solely by a licensed clinician after medical evaluation.
Program Duration and Commitment (Critical - Read This Carefully):
According to the company's FAQ and terms of use, programs are available in 1, 2, 4, or 6-month options. The company states that most patients begin with the "Jumpstart" option, which is a 4-month commitment.
Cancellation policy: According to the company's FAQ on the GLP-1 ID page at the time of publication, cancellation is not available once your selected program term has begun. Because GLP-1 medications are prescribed and shipped based on your selected program length, the commitment is for the full duration you select. This means if you sign up for a 4-month program and want to stop after month one, you can't cancel the remaining months. The company states this applies to all compounded medication purchases.
Early termination: According to the company's terms, if you do seek to end your program early, there may be administrative/restocking fees applied against any refund of unshipped medication. The specific fee structure depends on your plan duration. This fee may be waived if a provider determines you are medically ineligible to continue (for example, due to pregnancy or other documented contraindications). Review the full terms on the official website and at checkout for exact fee amounts before committing.
Medication refund policy: According to the company's returns policy page, all medications prescribed to you are non-refundable and cannot be returned. For damaged, lost, or stolen medications, the company states you should contact them within 48 hours at [email protected] or (877) 581-2210.
Medication shipping schedule: According to the company's terms, medication is dispensed in no more than two-month (56-day) increments, and continued shipment beyond the first supply is conditional on completing a required clinical follow-up around the eighth week.
Membership promotion: According to the company's website, Ivim Health currently offers the first month of membership at no additional cost.
How this compares to brand-name medication costs: For context, brand-name Wegovy carries a list price that, according to general industry data, can exceed $1,000 per month without insurance. Brand-name Zepbound similarly carries significant out-of-pocket costs without coverage. Ivim Health's compounded pricing is lower than the published list prices of certain brand-name GLP-1 medications without insurance coverage, according to publicly available pricing data - which is one of the primary reasons patients choose compounded options. However, the trade-off is that compounded medications lack the FDA review that brand-name products have undergone. This is a cost-versus-regulatory-certainty decision that each patient must make with their clinician.
You can verify current pricing and program details on the official Ivim Health website before committing.
The GLP-1 ID Patient Journey: Step by Step
Based on the company's website, here is what the Ivim Health experience looks like from start to ongoing care:
Step 1 - Eligibility and Intake: You complete a dynamic health questionnaire through the platform. According to the company's published study, patients must have a BMI of 30 or greater for inclusion. According to the company's terms, the service is intended for users 18 and older. Patients are screened for contraindications to GLP-1 therapy. Important eligibility note: GLP-1 medications are prescription treatments for obesity and overweight with related health conditions - not cosmetic weight loss tools. Eligibility for GLP-1 treatment is determined by a licensed clinician and typically involves BMI and medical history criteria. Not every person who completes the intake process will qualify for a prescription.
Step 2 - Provider Consultation: You meet with an Ivím Health provider via video or chat. According to the company's providers page, their clinical team includes board-certified obesity specialists and nurse practitioners. The consultation reviews your health history, goals, current medications, and determines whether GLP-1 therapy is appropriate for you. According to the company, the platform offers free same-day appointments.
Step 3 - Select Your Program and Start: If your provider determines treatment is appropriate, you select your program duration (1, 2, 4, or 6 months) and pay your program fee. Your provider finalizes your care plan and sends prescriptions to the partner pharmacy. Remember: once your program starts, it can't be cancelled.
Step 4 - Weekly Check-Ins and Dose Adjustments: According to the company, you complete a brief weekly check-in through the Ivim Health App. Your provider reviews your progress - symptoms, weight changes, side effects, how you are feeling - and makes dose adjustments as needed. This is the core of the individualized dosing model. According to the company's published study data, patients averaged a medical consultation once every 49 days, and over one-third of patients used the platform's virtual waiting room.
Step 5 - Medication Administration: According to the company's safety information, compounded semaglutide is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Dosing is determined by your prescribing clinician based on your individual response, health factors, and treatment goals. According to the company's published information, dosing may start at a lower level and be adjusted over time. Your provider guides your specific treatment regimen, and you should not change your dosing without discussing it with your provider first.
Step 6 - Refills and Ongoing Support: According to the company, refills are timed to your plan. Continued shipment is conditional on completing required clinical follow-ups. According to the company, patients have unlimited access to their care team throughout the program, including the ability to schedule unlimited video consultations.
Safety: What You Must Know Before Starting Any GLP-1 Medication
GLP-1 medications - whether compounded or brand-name - are prescription-strength pharmaceuticals that carry real risks alongside their benefits. According to prescribing information for GLP-1 receptor agonists, these medications may cause a range of side effects, and individual tolerability varies. You should understand what to expect before committing. The following is a high-level overview based on Ivim Health's published safety information and general GLP-1 prescribing literature - it is not a complete list of risks or precautions.
Most common side effects (according to the company's safety information): Nausea, vomiting, diarrhea, constipation, bloating or gas, and decreased appetite or early satiety. According to the company, these are typically gastrointestinal in nature, usually mild to moderate, and tend to improve over time with gradual dose escalation under provider supervision. According to the company's published study, over 95% of patients reported side effects as minimal or moderate but manageable. Adverse events related to any prescription medication may be reported to the FDA through the MedWatch program at 1-800-FDA-1088 or at fda.gov/medwatch.
Serious risks that require immediate medical attention (according to the company's safety information):
Serious allergic reactions - the company states to stop using the medication immediately and seek emergency care if you experience swelling of face, lips, tongue, or throat, severe rash or itching, rapid heartbeat, difficulty breathing or swallowing, or fainting.
Pancreatitis - GLP-1 medications are associated with potential pancreatic inflammation. Contact your provider immediately if you experience severe abdominal pain.
Gallbladder problems - including gallstones. Tell your provider about any history of gallbladder issues.
Changes in blood sugar - particularly important if you have diabetes. According to the company's safety information, combining GLP-1 medications with other glucose-lowering agents, especially sulfonylureas or insulin, may increase the risk of hypoglycemia.
Kidney problems - GLP-1 medications may affect kidney function, particularly in patients with pre-existing conditions.
Diabetic retinopathy complications - according to the company's safety information, patients with type 2 diabetes should tell their provider immediately about changes in vision.
Increase in heart rate - tell your provider if you experience a racing heartbeat while at rest.
Suicidal behavior and ideation - according to the company's safety information, patients should pay attention to mental health changes, especially sudden changes in mood, behaviors, thoughts, or feelings, and contact their provider immediately. Seek immediate medical attention or call 988 (Suicide and Crisis Lifeline) if experiencing suicidal thoughts.
Contraindications to be aware of: GLP-1 medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Semaglutide carries a boxed warning regarding thyroid C-cell tumors observed in animal studies, with unknown risk in humans. These medications are not recommended during pregnancy or breastfeeding.
Drug interactions to discuss with your clinician: According to the company's safety information, semaglutide causes a delay in gastric emptying, which can affect the absorption of oral medications. This is especially important for patients taking diabetes medications, insulin, or sulfonylureas. The company also notes that patients taking birth control pills by mouth should discuss alternatives with their provider, as oral contraceptives may not work as well while using semaglutide - the company recommends discussing another type of birth control for 4 weeks after starting semaglutide and for 4 weeks after each dose increase.
You are encouraged to report negative side effects of prescription products to the FDA at www.fda.gov/medwatch or by calling 1-800-FDA-1088.
This safety overview is not exhaustive and does not replace the Patient Drug Education or official prescribing information. Always review the full safety information provided with your prescription and consult your prescriber or pharmacist with any questions. This isn't a replacement for prescribed medical treatment for any health condition. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval.
Who Ivim Health's GLP-1 ID Program May Be Right For
The GLP-1 ID Program May Align Well With People Who:
Want more clinical touchpoints than a standard telehealth program: If you value weekly provider-reviewed check-ins and the ability to have your dose adjusted based on how YOUR body is responding - rather than following a fixed schedule - the individualized dosing model may offer a more hands-on experience. According to the company, patients have unlimited provider access and weekly dose adjustment opportunities.
Are looking for a lower published list price compared to brand-name alternatives without insurance coverage: If brand-name GLP-1 medications are financially out of reach - whether because of insurance denial, high copays, or no coverage - the compounded medication pricing (starting at approximately $75/month for semaglutide plus a $74.99 program fee, according to the company's FAQ) may make treatment accessible. Verify current pricing on the official website, as program structures and pricing may change.
Value published clinical evidence: If you want to see actual outcome data before committing - not just marketing claims - Ivim Health's published study in Obesity Pillars provides transparent results from over 1,100 patients. While the study has limitations (retrospective, self-selected population, company-authored), having published peer-reviewed data is uncommon in this market.
Prefer a comprehensive program beyond just medication: According to the company, the program includes holistic consultations, master classes, group coaching, community support, supplement discounts, and an app-based tracking experience. If you want more than just a prescription mailed to your door, this model may fit your preferences.
Are comfortable with compounded medications after understanding the distinction: If you have read the section above on compounded versus FDA-approved medications, discussed it with your primary care physician, and are comfortable proceeding with compounded formulations, this program may be appropriate.
Other Options May Be Preferable For People Who:
Require FDA-approved branded medications exclusively: While Ivim Health states it offers access to branded Wegovy and Zepbound through its traditional program, the GLP-1 ID program is primarily built around compounded formulations. If you specifically want an FDA-approved finished product and nothing else, confirm this option during your consultation or explore platforms that exclusively dispense branded medications.
Cannot commit to a multi-month program financially: According to the company's FAQ at the time of publication, cancellation is not available once your selected program term has begun - which means you need to be prepared for the full financial commitment of the duration you select. If you are uncertain, consider starting with the 1-month option rather than committing to 4 or 6 months. If financial flexibility is your top priority, explore platforms with month-to-month billing and easier cancellation terms.
Need or prefer in-person medical supervision: Some patients - particularly those with complex medical histories, multiple medications, or conditions requiring physical examination - may benefit more from working with an in-person obesity medicine specialist or endocrinologist. A virtual-first model, regardless of how many digital touchpoints it offers, has inherent limitations compared to hands-on clinical assessment.
Have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2: GLP-1 medications are contraindicated for these conditions. Any weight loss program should begin with a thorough medical evaluation, and this applies regardless of which platform you choose.
Are dealing with a GLP-1 plateau and want to switch to tirzepatide: If you have been on semaglutide and have stopped losing weight, tirzepatide (a dual GLP-1/GIP agonist) is an option some providers consider. According to the company's FAQ, Ivim Health offers compounded tirzepatide starting at approximately $133/month plus the $74.99 program fee. However, switching medications is a clinical decision that should be made with your provider based on your individual health profile.
Who Should Not Consider GLP-1 Therapy Without Specialist Oversight
Regardless of which telehealth platform you are evaluating, GLP-1 medications carry specific contraindications that require medical attention before proceeding. According to prescribing information and the company's safety disclosures, you should not use GLP-1 medications - or should only do so under specialist supervision - if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, active or recent pancreatitis, severe gastrointestinal disorders that may be worsened by delayed gastric emptying, are pregnant, planning to become pregnant, or breastfeeding, or have severe kidney disease. This is not an exhaustive list. A thorough medical evaluation by a licensed clinician is the only way to determine whether GLP-1 therapy is appropriate for your specific health profile.
Questions to Ask Yourself Before Choosing
Before committing to Ivim Health or any GLP-1 telehealth program, consider:
Am I comfortable with a primarily virtual healthcare experience, or do I prefer in-person medical visits?
Have I discussed GLP-1 medications with my primary care physician, especially regarding interactions with my current medications?
Do I understand the difference between compounded and FDA-approved medications, and am I comfortable with compounded formulations?
Can I commit financially to the full program duration I am selecting, knowing the cancellation policy?
Am I prepared for potential side effects, and do I have a plan to communicate with my provider if they occur?
What is my realistic timeline and weight loss expectation, and does it align with the clinical data (averages, not guarantees)?
Your answers help determine which GLP-1 program characteristics matter most for your specific situation.
How Ivim Health Compares to the Telehealth Weight Loss Landscape in 2026
The telehealth GLP-1 market has exploded since 2023, with dozens of platforms competing for your attention and your dollar. Without independent market data to make direct comparative claims, here are the factors worth evaluating when you research your options:
Published clinical evidence: Not all telehealth platforms have published peer-reviewed outcomes data. Ivim Health's study in Obesity Pillars is a concrete differentiator - though you should evaluate other platforms' evidence (or lack thereof) on the same terms.
Dosing model - individualized versus fixed escalation: According to the company, Ivim Health's weekly adjustment model differs from platforms that follow a standard dose escalation schedule. Whether this produces better outcomes for you depends on your individual medication response, side effect tolerance, and how closely your provider actually monitors your check-ins.
Total cost transparency: When comparing platforms, always calculate total monthly cost (medication plus program/membership/platform fees). A lower medication price can be offset by a higher program fee, and vice versa. According to the company's FAQ, Ivim Health's compounded options start at approximately $150-$208/month total (medication starting at $75-$133 plus a $74.99 program fee). Always verify current pricing directly before committing.
Cancellation flexibility: The multi-month commitment with no mid-program cancellation is a significant differentiator from some competitors that offer month-to-month billing. This is neither good nor bad - it depends on your confidence level and financial situation.
Provider network and clinical depth: According to the company, the platform maintains a nationwide provider network. The depth and quality of individual clinicians will shape your experience more than any marketing claims. Ask during your consultation about your assigned provider's experience with GLP-1 medications specifically.
Branded medication access: Not all compounded-GLP-1 platforms offer a pathway to FDA-approved branded medications. According to Ivim Health, patients can access branded Wegovy and Zepbound through the traditional program and the company supports prior authorization processes for insurance coverage.
Program breadth beyond medication: Some platforms are pure prescription-and-ship operations. According to Ivim Health, the program includes holistic consultations, coaching, community, and educational content. Whether you value these extras or just want the medication is a personal preference.
You can review eligibility requirements and current program options on the official Ivim Health GLP-1 ID page to determine whether a consultation makes sense for your situation.
How to Verify Ivim Health's Platform Standing Before You Commit
Regardless of what any review article tells you - including this one - you should perform your own due diligence before committing to any telehealth weight loss program. Here is a practical verification checklist:
Verify the business registration and address. According to the company's terms of use, Ivim Services LLC lists a registered office in Brighton, Michigan and a contact address at 4200 Regent Street, Suite 200, Columbus, Ohio. You can verify business registrations through the relevant state's secretary of state website.
Read the published clinical study yourself. The company's study is freely available on PubMed Central. Search "IVIM GLP-1 therapeutic outcomes" on PubMed or visit the direct link on the company's website. Reading the actual study - including its limitations section - gives you a much better understanding than any summary.
Read the full terms and conditions and returns policy before paying. Pay particular attention to the cancellation policy, medication refund terms, and program commitment structure. These are available on the company's website.
Verify your assigned provider's credentials. According to the company's providers page, its clinical team is licensed across 49 states. Your provider should be verifiable through your state's medical board. Ask for their name and license number during your consultation.
Confirm your specific insurance, HSA, or FSA situation. Do not assume coverage. Verify directly with your insurer and plan administrator whether compounded GLP-1 medications, telehealth consultations, or program fees are eligible for reimbursement under your specific plan.
Ask hard questions during your consultation. Specifically: What pharmacy will compound my medication? What happens if I have severe side effects between check-ins? How quickly can I reach my provider for urgent questions? What specific clinical experience does my provider have with GLP-1 medications?
Realistic Expectations: What GLP-1 Therapy Can and Cannot Do
Whether you choose Ivim Health or any other platform, setting realistic expectations is essential to a positive experience with GLP-1 therapy.
What GLP-1 medications can do (based on general clinical literature and the company's study): Help reduce appetite and food intake through multiple biological mechanisms. Support significant weight reduction when combined with lifestyle changes. According to the company's published data, patients on the IVIM protocol averaged 19.5% body weight reduction at 52 weeks - but this is an average across a specific study population, not a guarantee of your individual results.
What GLP-1 medications cannot do: Eliminate the need for healthy eating habits and physical activity. According to the company's safety information, compounded semaglutide should be used with a reduced-calorie diet and increased physical activity. GLP-1 medications are not a permanent solution on their own - research on weight regain after discontinuation is ongoing, and many patients experience some weight regain after stopping therapy. They cannot replace medical evaluation and management of underlying conditions that contribute to weight gain.
Timeline patterns (not guarantees): Ivim Health does not publish a specific week-by-week guaranteed timeline on their product page. Based on their study data, the weight reduction coefficient was approximately -0.739 pounds per week. Some patients may see noticeable changes within the first few months, while others may respond more gradually. Individual variability is significant and depends on starting weight, metabolic factors, medication adherence, dose optimization, lifestyle factors, and genetic variables.
The reality of side effects: According to the company's published study, over 95% of patients reported side effects as minimal or moderate. But 3.3% reported severe side effects. Gastrointestinal symptoms like nausea are common, especially during dose escalation periods. The individualized dosing model is designed to help manage this - but some discomfort during adjustment periods is a normal part of GLP-1 therapy.
This isn't a replacement for prescribed medical treatment. Consult your physician before beginning any prescription treatment program. Only a licensed clinician can decide whether GLP-1 therapy is appropriate for your specific case.
Contact Information
For questions before or during the program, according to the company's website, Ivim Health offers customer support:
Phone: (877) 581-2210
Email: [email protected]
Address: 4200 Regent Street, Suite 200, Columbus, OH 43219
You can view the current offer and confirm today's pricing on the official Ivim Health GLP-1 ID page before reaching out.
Decision Framework: Who This Program May Fit in 2026
The Case for Ivim Health
In a telehealth weight loss market where many platforms offer little more than a questionnaire and a shipped vial, Ivim Health highlights several distinguishing features. The published clinical data - 19.5% average body weight reduction at 52 weeks across 1,131 patients, published in a peer-reviewed journal (this outcome reflects a retrospective analysis of program completers and should not be interpreted as typical or guaranteed) - is a published peer-reviewed evidence base, which is uncommon among telehealth GLP-1 platforms. The individualized dosing model with weekly provider-reviewed check-ins represents a higher-touch monitoring model compared to fixed-schedule escalation alternatives. Pricing shown in the company's FAQ at the time of publication listed compounded semaglutide starting at approximately $75/month plus a $74.99 program fee - always verify current pricing before enrolling. And the breadth of the program - holistic consultations, coaching, community, app-based tracking - suggests an approach that treats weight loss as a comprehensive health journey rather than a transaction. No independent head-to-head trials comparing Ivím Health's protocol to other telehealth GLP-1 programs were identified at the time of publication.
Considerations to Weigh
According to the company's FAQ at the time of publication, cancellation is not available once your selected program term has begun - which is the most significant friction point. You need to be financially prepared for the full commitment before you start. The compounded medication distinction is real and important - these products lack the FDA review that branded alternatives have undergone, and you should be fully comfortable with this after your own research and physician consultation. The quality of your experience will depend on your individual provider, not just the platform's marketing. And the published study, while valuable, was retrospective, company-authored, and lacks a control group - limitations that any informed consumer should weigh alongside the results.
Important Regulatory Context
The compounded GLP-1 medication space has been under ongoing regulatory scrutiny. The FDA determined in February 2025 that the semaglutide shortage had ended, which has implications for the regulatory environment around compounded semaglutide. Patients should review the most current regulatory information and confirm that any platform they use is operating in compliance with current federal and state compounding regulations before proceeding.
The Bottom Line
If you have been considering GLP-1 therapy for weight management and you value a program backed by published clinical data, with weekly clinical oversight, at a price point lower than the published list prices of certain brand-name GLP-1 medications without insurance coverage (according to publicly available pricing data), Ivim Health's GLP-1 ID program may warrant a clinical evaluation if you meet BMI criteria and understand the compounded medication distinction. But that evaluation should happen after you have read the full terms, understood the compounded medication distinction, discussed GLP-1 therapy with your primary care physician, confirmed your financial readiness for the program commitment, and asked hard questions during your consultation.
The right weight management program is one that aligns with your health profile, your financial situation, and your expectations - with full transparency about regulatory status, program terms, and what the evidence actually shows.
Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval. Only a licensed clinician can decide whether GLP-1 therapy is appropriate for your specific case.
You can view the current Ivim Health GLP-1 ID offer on the official Ivim Health page to confirm pricing, eligibility, and terms before scheduling a consultation.
Frequently Asked Questions About Ivim Health GLP-1 ID
Is Ivim Health a registered, verifiable company?
Short answer: Public business records show Ivim Services LLC is a registered company, and the company lists verifiable contact information, published customer support channels, and a peer-reviewed clinical study. Readers should independently review registration records, terms, compounded medication status, cancellation policies, and licensing before enrolling.
According to publicly available information, Ivim Health (Ivim Services LLC) is a registered company that lists its contact address at 4200 Regent Street, Suite 200, Columbus, OH 43219, with a registered office referenced in Brighton, Michigan in the company's terms of use. The company was founded in 2021 by Dr. Taylor Kantor, alongside his brother Anthony and Anthony's wife, Kelly, according to the company's website. The company operates across 49 U.S. states and has published clinical outcomes data in the peer-reviewed journal Obesity Pillars, indexed on PubMed Central. The company lists a customer support phone number at (877) 581-2210 and a support email at [email protected].
Are Ivim Health's GLP-1 medications FDA-approved?
Short answer: The GLP-1 ID program primarily uses compounded medications, which are not FDA-approved finished products. The platform itself is not an FDA-approved entity. Patients who prefer branded medications can access FDA-approved options through the company's traditional GLP-1 program.
The GLP-1 ID program primarily uses compounded semaglutide and compounded tirzepatide. Compounded medications are not reviewed or approved by the FDA as finished products and have not undergone FDA review for safety, effectiveness, or quality. They are prepared by licensed pharmacies based on individual prescriptions. According to the company, patients who prefer branded medications can access FDA-approved Zepbound and Wegovy through the traditional GLP-1 program.
Is compounded semaglutide legal in 2026?
Short answer: As of this writing, compounded semaglutide may be prepared legally by licensed pharmacies under federal law when based on an individual prescription, though the regulatory landscape is actively evolving.
Compounded semaglutide may be prepared legally by licensed pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act when based on an individual prescription from a licensed practitioner. However, the regulatory environment around compounded semaglutide has been evolving - the FDA determined in February 2025 that the branded semaglutide shortage had ended, which has implications for ongoing compounding practices. Patients should stay informed about current FDA guidance and confirm that their telehealth platform and pharmacy are operating in compliance with current federal and state compounding regulations.
What is compounded semaglutide and is it the same as Wegovy?
Short answer: Compounded semaglutide contains the same active ingredient as Wegovy but is not the same product. It hasn't undergone FDA review as a finished product.
Compounded semaglutide contains the same active ingredient as Wegovy (manufactured by Novo Nordisk), but it is not the same product. According to Ivim Health's own disclaimers, the compounded semaglutide products are not made by Novo Nordisk or any affiliated company. Compounded medications are prepared by licensed compounding pharmacies and have not undergone FDA review for safety, effectiveness, or quality as finished products. According to the company's compounded semaglutide page, "Ivím only selects FDA-inspected, state-regulated compounding pharmacies that meet regulatory board standards for quality and safety." Inspection of a pharmacy does not mean the compounded finished product itself is FDA-approved.
How much does Ivim Health cost per month?
Short answer: According to the company's FAQ, total estimated monthly cost starts at approximately $150 for compounded semaglutide ($75 medication + $74.99 program fee) or approximately $208 for compounded tirzepatide ($133 + $74.99). Always verify current pricing before committing.
According to the company's FAQ, compounded semaglutide starts at approximately $75/month and compounded tirzepatide starts at approximately $133/month, plus a $74.99/month membership/program fee. Total estimated monthly cost ranges from approximately $150 to $208 depending on your medication choice, per the company's published FAQ. The company's GLP-1 ID marketing page may display different bundled figures. Always verify current pricing on the official website before committing.
Can I cancel my Ivim Health program?
Short answer: According to the company's FAQ at the time of publication, cancellation is not available once your selected program term has begun. Programs range from 1 to 6 months, and early termination may incur fees.
According to the company's terms of use and FAQ at the time of publication, cancellation is not available once your selected program term has begun. Programs are structured based on the duration you select at checkout - 1, 2, 4, or 6 months. Early termination incurs administrative/restocking fees per the company's terms. This fee is waived if a provider determines you are medically ineligible to continue. Review the full terms on the official website before committing.
What are the side effects of compounded semaglutide?
Short answer: The most common side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation). Serious risks exist and are listed below.
Per the company's safety information, the most common side effects are gastrointestinal - nausea, vomiting, diarrhea, constipation, bloating, and decreased appetite. The company's published study found that over 95% of patients reported side effects as minimal or moderate. Serious potential risks include allergic reactions, pancreatitis, gallbladder problems, changes in blood sugar, kidney problems, increased heart rate, and mental health changes. GLP-1 medications carry a boxed warning regarding thyroid C-cell tumors observed in animal studies.
Does insurance cover Ivim Health?
Short answer: Most compounded medications are not covered by traditional insurance, but coverage varies by plan. Always verify with your insurer.
Many direct-to-consumer prescription products are not covered by traditional insurance plans, but coverage policies vary. According to the company, Ivim Health supports prior authorization processes for patients seeking insurance coverage for branded GLP-1 medications. Compounded medications may be eligible for HSA/FSA reimbursement, according to the company. Always confirm with your specific insurer and plan administrator.
Can I use my HSA or FSA card to pay for Ivim Health?
Short answer: The company states HSA and FSA cards are accepted for compounded medication purchases. Verify with your plan administrator.
The company states that compounded semaglutide medication can be paid for with HSA or FSA cards. Verify eligibility with your specific plan administrator, as policies and qualifying expenses vary between plans.
How is Ivim Health different from Hims, Ro, or other telehealth GLP-1 platforms?
Short answer: Without independent comparative data, direct superiority claims can't be made. Key claimed differentiators include individualized dosing, published clinical data, and a comprehensive care model.
Without independent comparative data, we cannot make direct superiority claims. According to Ivim Health, the key differentiators include the individualized dosing model with weekly provider check-ins, published peer-reviewed clinical data, access to both compounded and branded medications, and a comprehensive program including holistic consultations and coaching. The best comparison is made by reviewing each platform's specific terms, pricing, cancellation policies, published evidence, and clinical model.
What happens when I stop taking GLP-1 medication?
Short answer: Many patients experience some weight regain after stopping GLP-1 medication. This applies to all GLP-1 therapy, not just Ivim Health.
This is an important question that applies to all GLP-1 therapy, not just Ivim Health. Research on weight regain after discontinuation is ongoing. Many patients experience some weight regain after stopping GLP-1 medication. According to the company, the program length is designed for sustained use, and discussions about extending treatment or transitioning to maintenance should take place with your provider. This decision should always be made with clinical guidance.
Does Ivim Health work for people with PCOS, menopause, or insulin resistance?
Short answer: GLP-1 medications have been studied in various populations, but appropriateness for your individual health profile can only be determined by the clinician who evaluates you.
GLP-1 medications have been studied in various populations, and many people with these conditions may be candidates for therapy. However, the specific appropriateness of GLP-1 medication for your individual health profile - including any co-existing conditions - can only be determined by the licensed clinician who evaluates you during your consultation. Discuss your complete health history during your intake.
How fast does Ivim Health GLP-1 work?
Short answer: The company's study reported an average of approximately 0.74 pounds per week. Individual timelines vary significantly and no guaranteed timeline is published.
The company's published study reported a weight reduction coefficient of approximately 0.74 pounds per week on average. Individual timelines vary significantly. The company doesn't publish a guaranteed week-by-week timeline. Some patients may notice changes within the first few weeks to months, while others respond more gradually. Your provider will monitor your progress through weekly check-ins and adjust your plan accordingly.
Disclaimers
Content and Medical Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. The descriptions of potential benefits are not guarantees and are not a substitute for an individualized medical evaluation. GLP-1 medications available through Ivim Health are compounded prescription medications that require evaluation by a licensed clinician. The information provided here does not replace the professional judgment of your healthcare provider.
Professional Medical Disclaimer: This article is educational and does not constitute medical advice. GLP-1 medications are not a substitute for prescribed medical treatment. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting any new prescription treatment. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval.
Compounded Medication Notice: Ivim Health's GLP-1 ID program uses compounded semaglutide and compounded tirzepatide prepared by licensed pharmacies based on individual prescriptions. Compounded medications are not reviewed or approved by the FDA as finished products and have not undergone FDA review for safety, effectiveness, or quality. According to the company's compounded semaglutide page, "Ivím only selects FDA-inspected, state-regulated compounding pharmacies that meet regulatory board standards for quality and safety." Inspection of a pharmacy by the FDA does not mean the compounded finished product itself is FDA-approved or that the FDA has verified the safety or quality of the finished compounded product.
Results May Vary: Individual results will vary based on factors including age, baseline health condition, starting weight, BMI, metabolic factors, consistency of use, genetic factors, current medications, lifestyle choices, dietary habits, physical activity level, and other individual variables. While patients in the company's published study achieved an average of 19.5% body weight reduction at 52 weeks, results are not guaranteed. The clinical outcomes cited represent averages from a specific study population and may not reflect your individual experience. Patients who complete clinical studies may be more motivated than average, and results should not be assumed to be typical.
FTC Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you.
Pricing Disclaimer: All prices, program fees, membership costs, discounts, and promotional offers mentioned were accurate at the time of publication (February 2026) but are subject to change without notice. Always verify current pricing and terms on the official Ivim Health website before making your purchase.
Publisher Responsibility: The publisher of this article has made every effort to ensure accuracy at the time of publication. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with Ivim Health and their healthcare provider before making decisions.
Insurance Coverage Note: Many direct-to-consumer prescription products are not covered by traditional insurance plans, but coverage policies vary. Always confirm benefits directly with your insurer. Some HSA/FSA plans may reimburse qualifying expenses; check your specific plan rules.
Privacy and Health Information Notice: Telehealth services involve the collection and transmission of personal health information. Review Ivím Health's Privacy Policy and HIPAA Notice on the official website before enrolling to understand how your health data is collected, stored, and used.
SOURCE: Ivim Health